CLAIMS

1. A method for producing a composition comprising an influenza HA split vaccine antigen and a vaccine adjuvant, comprising the following steps:

a) producing an influenza HA split vaccine antigen which produces an antibody that binds to a LAH of a HA stem region by subjecting an influenza HA split vaccine which has not undergone a formalin treatment to an acidic treatment, wherein the acidic treatment is performed at a pH of 4.0 to 6.0; and

b) mixing the vaccine antigen obtained in step a) with the vaccine adjuvant.

2. A method for producing a composition comprising an influenza HA split vaccine antigen and a vaccine adjuvant, comprising the following steps:

a) subjecting an influenza HA split vaccine to an acidic treatment, wherein the acidic treatment is performed at a pH of 4.0 to 6.0,

b) thereafter, conducting a formalin treatment to obtain an influenza HA split vaccine antigen which produces an antibody that binds to a LAH of a HA stem region; and

c) mixing the vaccine antigen obtained in step b) with the vaccine adjuvant.

3. A method for producing a kit comprising an influenza HA split vaccine antigen and a vaccine adjuvant, comprising the following steps:

a) producing an influenza HA split vaccine antigen which produces an antibody that binds to a LAH of a HA stem region by subjecting an influenza HA split vaccine which has not undergone a formalin treatment to an acidic treatment, wherein the acidic treatment is performed at a pH of 4.0 to 6.0; and

b) combining the vaccine antigen obtained in step a) with the vaccine adjuvant to form a kit.

4. A method for producing a kit comprising an influenza HA split vaccine antigen and a vaccine adjuvant, comprising the following steps:

a) subjecting an influenza HA split vaccine to an acidic treatment, wherein the acidic treatment is performed at a pH of 4.0 to 6.0,

b) thereafter, conducting a formalin treatment to obtain an influenza HA split vaccine antigen which produces an antibody that binds to a LAH of a HA stem region; and

c) combining the vaccine antigen obtained in step b) with the vaccine adjuvant to form a kit.